Quick Answer
Aurinia Pharmaceuticals Inc. reported Operating Income Loss of $104.91 million for the year ending 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +2,338.4% in Operating Income Loss from 2024 to 2025.
- This data is from Aurinia Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Aurinia Pharmaceuticals Inc.'s Operating Income Loss has grown by 289.9%.
- Historical annual values: Fiscal year 2025: $104.91 million | Fiscal year 2024: -$4.69 million | Fiscal year 2023: -$91.69 million | Fiscal year 2022: -$111.47 million | Fiscal year 2021: -$180.74 million | Fiscal year 2020: -$104.29 million | Fiscal year 2019: -$90.94 million | Fiscal year 2018: -$55.24 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: